CryoPort, Inc. (NASDAQ:CYRX) Receives $12.56 Consensus PT from Analysts

CryoPort, Inc. (NASDAQ:CYRX) has been given an average rating of “Buy” by the ten analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $12.5556.

Several research firms have issued reports on CYRX. Leerink Partners raised CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Wednesday, August 6th. KeyCorp raised CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price target on the stock in a research note on Wednesday, August 6th. Leerink Partnrs raised shares of CryoPort from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 6th. BTIG Research boosted their price objective on shares of CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Finally, Stephens assumed coverage on CryoPort in a research report on Tuesday, July 22nd. They set an “overweight” rating and a $13.00 price target for the company.

CryoPort Price Performance

NASDAQ CYRX opened at $9.50 on Monday. The business has a 50 day simple moving average of $8.77 and a 200 day simple moving average of $7.21. CryoPort has a 52-week low of $4.58 and a 52-week high of $10.46. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The stock has a market cap of $475.67 million, a price-to-earnings ratio of 7.14 and a beta of 1.61.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%.The business had revenue of $45.45 million for the quarter, compared to the consensus estimate of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Analysts anticipate that CryoPort will post -0.99 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Robert Stefanovich sold 9,300 shares of CryoPort stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total value of $80,631.00. Following the completion of the transaction, the chief financial officer owned 207,213 shares of the company’s stock, valued at $1,796,536.71. This trade represents a 4.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ramkumar Mandalam sold 40,728 shares of CryoPort stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total transaction of $294,870.72. Following the completion of the transaction, the director directly owned 92,328 shares of the company’s stock, valued at approximately $668,454.72. This trade represents a 30.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 80,028 shares of company stock valued at $661,252 in the last quarter. Company insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Rhumbline Advisers increased its holdings in shares of CryoPort by 23.8% during the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company’s stock worth $476,000 after acquiring an additional 15,036 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in CryoPort by 154.5% in the 1st quarter. Russell Investments Group Ltd. now owns 32,761 shares of the company’s stock valued at $199,000 after acquiring an additional 19,886 shares during the period. ProShare Advisors LLC bought a new position in CryoPort in the 4th quarter valued at about $95,000. CWM LLC raised its holdings in CryoPort by 1,437.0% in the 1st quarter. CWM LLC now owns 11,328 shares of the company’s stock valued at $69,000 after acquiring an additional 10,591 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in CryoPort by 7.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company’s stock valued at $8,135,000 after acquiring an additional 73,949 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.